Corcept Therapeutics Incorporated

CORT • Medical - Pharmaceuticals

$111.62

▼ -1.18 (-1.05%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$13.21B

Crecimiento

—

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 13.1%Crecimiento positivo de ingresos · 23.4%Flujo de caja libre positivo · 1.37Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.01

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$111.62

Change-1.05%

Shares Out118.39M

Market Cap$13.21B

Enterprise Value$12.92B

52W Range28.66 - 122.21

Beta0.46

P/E240.72

P/S15.91

P/B18.72

P/FCF123.59

EV/Sales15.55

Price$111.62

Change-1.05%

Shares Out118.39M

Market Cap$13.21B

Enterprise Value$12.92B

52W Range28.66 - 122.21

Beta0.46

P/E240.72

P/S15.91

P/B18.72

P/FCF123.59

EV/Sales15.55

EV/EBITDA1,753.85

EV/FCF120.79

Earnings Yield0.42%

FCF Yield0.81%

Dividend Yield0.00%

Gross Margin98.30%

Oper. Margin5.88%

Profit Margin13.09%

Debt/Eq0.01

Current Ratio2.92

Quick Ratio2.85

Target$125.33

Target Upside12.28%

Target Median$142.50

Target Range50.00 - 165.00

Volume4.45M

Avg Volume1.21M

EPS Surprise-0.16

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

48/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

59/100

Atractivo del precio

Barata o cara hoy

45/100

Por qué este puntaje▼

Márgenes estables o en mejora · 13.1%Crecimiento positivo de ingresos · 23.4%Flujo de caja libre positivo · 1.37Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.01Liquidez saludable · 2.92

Analyst view

Analyst sentiment and price target

CORT

Analyst sentiment

Based on 26 analyst votes · 2026-09-05

71/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-31

Bajo

$50.00

Promedio

$117.60

Mediana

$135.00

Alto

$165.00

Resumen de la compañía

IPO: 4/14/2004

Industria: Medical - Pharmaceuticals

P/B i: 18.72

Deuda / Patrimonio i: 0.01

Margen operativo: 5.88%

Margen neto: 13.09%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 2.92

Ratio rápido: 2.85

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Mokari Atabak

Transacción: 07/15/2026

VENTA

Cambio

-101

Precio

$89.43

Presentación

07/17/2026

Tipo

VENTA

Mokari Atabak

Transacción: 07/15/2026

VENTA

Cambio

-15,833

Precio

$19.26

Presentación

07/17/2026

Tipo

VENTA

WILSON JAMES N

Transacción: 07/15/2026

VENTA

Cambio

-1,978

Precio

$89.49

Presentación

07/17/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Mokari Atabak	VENTA	-101	$89.43	07/15/2026	07/17/2026
Mokari Atabak	VENTA	-15,833	$19.26	07/15/2026	07/17/2026
WILSON JAMES N	VENTA	-1,978	$89.49	07/15/2026	07/17/2026
Guyer William	VENTA	-952	$93.54	07/07/2026	07/08/2026
Guyer William	VENTA	-20,000	$21.65	07/07/2026	07/08/2026
Robb Gary Charles	VENTA	-600	Not reported	05/27/2026	07/08/2026
Maduck Sean	VENTA	-11,175	$89.31	07/01/2026	07/06/2026
Maduck Sean	VENTA	-25,000	$8.27	07/01/2026	07/06/2026
MAHONEY DAVID L	VENTA	-20,000	$84.53	06/17/2026	06/18/2026
WILSON JAMES N	VENTA	-5,823	$83.57	06/16/2026	06/18/2026
Mokari Atabak	VENTA	-40,000	$19.26	06/15/2026	06/17/2026
Mokari Atabak	VENTA	-2	$82.45	06/15/2026	06/17/2026
Guyer William	VENTA	-20,000	$70.60	06/02/2026	06/04/2026
Guyer William	VENTA	-20,000	$21.65	06/02/2026	06/04/2026
Robb Gary Charles	VENTA	-358	$70.44	06/02/2026	06/03/2026
Mokari Atabak	VENTA	-395	$70.44	06/02/2026	06/03/2026
Maduck Sean	VENTA	-452	$70.44	06/02/2026	06/03/2026
Lyon Joseph Douglas	VENTA	-269	$70.44	06/02/2026	06/03/2026
Robb Gary Charles	COMPRA	+776	$70.44	06/01/2026	06/03/2026
Mokari Atabak	VENTA	-40,000	$70.00	06/01/2026	06/03/2026

Sobre la compañía

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Fuente - Link

Competidores

ABVX AXSM CAI CYTK HALO JAZZ MRUS NUVL RNA RYTM

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT

Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,736 shares of the biotechnology company's stock after acquiring an additional 28,078 shares during the period. Bank

Defense World

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT

Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 565,666 shares of the biotechnology company's stock, valued at approximately $49,185,000. Bank of New York Mellon Corp owned approximately

Defense World

BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT

BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,432,023 shares of the biotechnology company's stock, valued at approximately $1,080,964,000. BlackRock Inc. owned about 11.50% of

Defense World

Like The Knick's, Corcept Rebounded And Is Crushing It

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-30	-0.142	-0.3	-0.158
2026-02-24	0.33	0.2	-0.13
2025-11-04	0.18	0.16	-0.02
2025-07-31	0.23	0.29	0.06
2025-05-05	0.17	0.17	0
2025-02-26	0.37	0.26	-0.11
2024-10-30	0.28	0.41	0.13
2024-07-29	0.23	0.32	0.09
2024-05-01	0.22	0.25	0.03
2024-02-15	0.26	0.28	0.02
2023-11-01	0.22	0.28	0.06
2023-08-02	0.15	0.25	0.1